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ABSTRACT
Background: SPG10 is an autosomal dominant form of
hereditary spastic paraplegia (HSP), which is caused by
mutations in the neural kinesin heavy chain KIF5A gene,
the neuronal motor of fast anterograde axonal transport.
Only four mutations have been identified to date.
Objective: To determine the frequency of SPG10 in
European families with HSP and to specify the SPG10
phenotype.
Patients and methods: 80 index patients from families
with autosomal dominant HSP were investigated for
SPG10 mutations by direct sequencing of the KIF5A motor
domain. Additionally, the whole gene was sequenced in
20 of these families.
Results: Three novel KIF5A mutations were detected in
German families, including one missense mutation
(c.759G.T, p.K253N), one in frame deletion
(c.768_770delCAA, p.N256del) and one splice site
mutation (c.217G.A). Onset of gait disturbance varied
from infancy to 30 years of age. All patients presented
clinically with pure HSP, but a subclinical sensory–motor
neuropathy was detected by neurophysiology studies.
Conclusions: SPG10 accounts for approximately 3% of
European autosomal dominant HSP families. All mutations
affect the motor domain of kinesin and thus most likely
impair axonal transport. Clinically, SPG10 is characterised
by spastic paraplegia with mostly subclinical peripheral
neuropathy.
Hereditary spastic paraplegia (HSP) is a clinically and
genetically heterogeneous group of disorders that
share the key symptom of lower extremity spasticity
due to progressive degeneration of the corticospinal
tract.1 2 At present, at least 32 loci for HSP, termed
SPG1-37, are known, including nine genes for
autosomal dominant disease.3 SPG3A (10%) and
SPG4 (40–50%) are the most frequent forms, respon-
sible for more than 50% of dominant HSP cases.4 5
SPG10 is an autosomal dominant HSP (adHSP)
caused by mutations in the gene encoding kinesin
heavy chain KIF5A, the motor of anterograde
axonal transport.6 To date, only four mutations
have been described, three of them located in the
KIF5A motor domain and one in the adjacent
coiled coil domain.6–9
To determine the frequency of SPG10 in
German, Dutch, Austrian and Serbian families
with HSP and to define the phenotype of SPG10,
we investigated index patients from families with
adHSP by direct sequencing of the KIF5A gene.
PATIENTS AND METHODS
Eighty index patients from German (n = 41),
Dutch (n = 25), Austrian (n = 9) and Serbian
(n = 5) families segregating spastic paraplegia in
an autosomal dominant manner were included in
this study following established diagnostic cri-
teria.10 11
Spastin mutations (SPG4) had been excluded by
direct sequencing or dHPLC in 51 of 80 patients
(64%).
The study was approved by the local ethics
committee (Vote 277/2004). Informed and written
consent was obtained from all participants.
DNA was extracted from blood samples follow-
ing standard procedures.
Direct sequencing of the kinesin motor domain,
encoded by exons 1–11 of the KIF5A gene
(NM004984), was performed in all index patients.
In 20 of the German index patients, the whole
coding sequence (exons 1–28) was analysed (see
supplement online for experimental details and
primer sequences).
Nerve conduction studies were performed
according to standard techniques. Motor evoked
potentials were recorded from the first dorsal
interosseus and tibialis anterior muscle using a
circular coil according to standard techniques.12
RESULTS
Sequencing of the KIF5A gene
Mutational screening in 80 index patients revealed
three novel mutations in the KIF5A motor domain,
including one missense mutation (c.759G.T,
p.K253N), one in frame deletion
(c.768_770delCAA, p.N256del) and one splice site
mutation (c.217G.A). None of these sequence
variations was present in 384 unrelated control
alleles. Cosegregation with the disease was shown
where possible (fig 1).
Interestingly, residue N256 that is deleted by the
c.768_770delCAA mutation was shown to cause
HSP when replaced by serine in a British family.6
The c.217G.A nucleotide exchange affects a
potential splice donor site and reduces splicing
efficiency from 81% to 0%, as predicted by
NNSPLICE 0.9.13 The effect of the c.217 G.A
mutation on mRNA splicing could not be tested
experimentally as KIF5A is not expressed in
peripheral blood and no other tissue samples were
available from the affected patient.
All three novel mutations are predicted to affect
protein function using programs designed to predict
deleterious effects of nucleotide exchanges based on
sequence homologies and physical amino acid proper-
ties (SIFT: http://blocks.fhcrc.org/sift/sift.html).
The kinesin motor domain, corresponding to
amino acid residues 1–324, is highly conserved
within the human kinesin family as well as
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between species (see supplementary fig 1 online). The three
novel mutations found in this screen all affect highly conserved
amino acid residues in the motor domain (see supplementary fig
2 online). No mutations outside the motor domain (exons 1–11)
were detected in the 20 subjects in whom the whole KIF5A gene
was sequenced.
SPG10 mutations were found in 3 of 41 (7%) German adHSP
families. No mutations were detected in Dutch, Austrian or
Serbian families. In the total cohort, the frequency of SPG10
mutations was 3/80 (4%).
Clinical description and electrophysiological characteristics of
SPG10 patients
SPG10-01
The six affected members of family SPG10-01 presented with a
pure form of HSP with onset of gait disturbance between early
infancy and adulthood (mean age at onset 15.7 years (range 2–
30)). All patients were still ambulant at the time of examination
despite disease duration of more than 50 years in one family
member (II-5). Three affected family members suffered from
postural and action tremor of the hands consistent with the
diagnosis of essential tremor that segregated independently in
this family.
Apart from mild reduction of vibration sense distally in the
legs, no sensory deficits were observed. Other symptoms or
signs of lower motor involvement were absent.
Neurophysiological examination, however, revealed subclinical
peripheral neuropathy of the sensor–motor type with axonal
and demyelinating features (table 1).
SPG10-02
The index patient of family SPG10-02 (II-1) developed a
progressive spastic gait disturbance at 19 years of age. At age
29 years she was diagnosed with multiple sclerosis because of
left-sided hemiparesis responding to cortisone pulse therapy,
immunoreactive CSF syndrome and multiple hyperintense,
partially contrast enhancing, predominantly periventricular
but also spinal lesions on MRI. Additionally, sensory–motor
neuropathy was noted. Sural nerve biopsy revealed chronic
axonal neuropathy without signs of inflammation. Family
history was positive with the mother also being affected by
spastic gait. On examination, visual acuity was reduced on the
right eye with optic atrophy on fundoscopy. Sensory deficits
included impaired vibration and joint position sense. Further
findings are presented in table 1.
SPG10-03
The index patient of family SPG10-03 (II-2) reported onset of a
spastic gait disturbance at the age of 51 years. On inquiry,
however, she recognised a Trendelenburg-like gait, particularly
during running, since young adulthood. Only after replacement
of both hip joints due to arthritis at the age of 51 years did this
gait abnormality became more obvious in everyday life and was
noted to be progressive. In addition to spastic paraplegia, subject
II-2 suffered from bladder and bowel urge incontinence. No
signs and symptoms of complicated disease were noted.
DISCUSSION
SPG10 was initially regarded as an infantile onset form of
HSP.6 7 In agreement with two previously described SPG10
families8 9 however, our families demonstrated that age at onset
is actually quite variable and ranges from early childhood until
the third decade of life.
The classification of HSP into pure and complicated forms is
based on clinical criteria.10 Using these criteria, SPG10 presents
as a clinically pure form of HSP with only mild amyotrophy
Figure 1 Pedigrees of SPG10 families; electropherograms and cosegregation of the mutations. (A) Pedigree of family SPG10-01, modified to ensure
confidentiality. The c.759G.T mutation was verified in all six living affected family members. No unaffected family members carried the mutation. This
mutation leads to replacement of lysine by asparagine at amino acid position 253 (K253N). (B) Pedigree of family SPG10-02. The index patient (II-2) as
well as her affected mother carry a heterozygous three base pair deletion at position 768_770 of the coding sequence, resulting in an inframe deletion
of asparagine at amino acid position 256. (C) Pedigree of family SPG10-03. A nucleotide exchange at position 217 of the coding sequence leads to loss
of a splice donor site in the index patient (II-2). Filled symbols denote affected individuals, open symbols denote unaffected individuals; deceased family
members are marked by a slash.
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occurring occasionally in the later stages of the disease.
However, subclinical involvement of the sensory and motor
peripheral nervous system was noted in all SPG10 patients
examined neurophysiologically. This is in accordance with pan-
neuronal expression of KIF5A, that has been shown in mice.14 As
KIF5A mutations are most likely to affect axonal transport, it is
plausible that neurons with particularly long axonal processes
such as those constituting the corticospinal tract, dorsal
columns and peripheral nerves would be affected in SPG10.
In all SPG10 families reported to date and also in the large
German family described here, KIF5A mutations showed 100%
penetrance. SPG10 is slowly progressive and follows a rather
benign course; none of our patient has lost the ability to walk
even after more than 50 years into the disease.
The frequency of SPG10 among adHSP has not been
investigated previously. We screened 80 index patients of
adHSP families from central Europe for KIF5A mutations and
detected three mutations (,4%). Spastin mutations had been
previously excluded in 51 of our patients. As about 60% of
adHSP are SPG4 negative,15 correction for this inclusion bias
yields a SPG10 frequency of ,3% in European adHSP families
(3/(29+51/0.6)). It has to be noted, however, that no mutations
were detected in Dutch, Austrian or Serbian families.
None of the four previously published KIF5A mutations6–9
were identified in our sample. It is remarkable, however, that
five of the now seven known KIF5A mutations, including
K253N and N256del identified in this study, are located in the
switch cluster, encoded by exons 9 and 10 of the KIF5A gene.
The switch cluster senses the x-phosphate in bound nucleotide
and triggers nucleotide dependent conformational changes in
the motor.16 Replacement of the KIF5B homologue of K253
(K252) by alanine has been shown to interfere with microtubule
dependent ATPase activation and ATP turnover rate in vitro.17
The N256 mutations, as indicated by Reid et al, might cause
decoupling of nucleotide and microtubule binding of the
motor.18 The putative splice site mutation c.217G.A is
predicted to result in omission of exon 3 which would lead to
loss of the p-loop (N1) that is essential for the interaction of
kinesin motor and ATP. This suggests that ATP hydrolysis and
microtubule binding of KIF5A might be key targets of HSP
pathogenic mutations.
Pure adHSPs differ little in their clinical presentation and the
discriminating features that might exist are often lost in the
noise of phenotypic variability of specific adHSP subtypes. With
nine dominant HSP genes known to date, containing nearly
16 kB of coding sequence, pragmatic guidelines for genetic
testing are warranted. We suggest genetic testing for SPG10 in
families with pure forms of HSP and onset before 45 years of
age in all affected family members. Although no clusters of
SPG10 mutations have been found, all private mutations
identified so far are located in the kinesin motor domain.
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Table 1 Clinical and neurophysiological features of SPG10 patients
SPG10-01 SPG10-02 SPG10-03
II-5 II-10 III-3 III-9 III-10 II-1 II-2
Clinical characteristics
Age at examination (y) 56 47 21 25 19 32 58
Sex M M M F F F F
Age at onset (y) 2 30 21 4 15 19 Young
adulthood
Disease duration (y) 54 17 0.5 21 4 13 .30
Degree of disability* (3) (1) (1) (1) (1) (2) (3)
Weakness (LL) + + + + + + +
Muscle wasting – – – – – – –
Spasticity (UL) – – – – – – –
Spasticity (LL) + + + + + + +
Hyperreflexia (LL) + + + + + + + (PSR q)
Hyporeflexia (LL) – – – – – + (ASR
missing)
+ (ASR
missing)
Babinski’s sign + – + + + + +
Impaired vibration sense (LL) + + – + +
Urinary urgency + + – + + + +
Neurophysiology
MNCV tibial nerve (N .41 m/s) 40.0 33.1 39.9 36.7 40
CMAP tibial nerve (N .10 mV) 2.3 1.0 4.6 2.2 22.1
F latency tibial nerve (N ,55 ms) 46.7 No F waves 53.3 No F waves 51.4
SNCV sural nerve (N .45 m/s) 52 48 40 52
SNAP sural nerve (N .10 mV) 2.1 1.0 3.2 No SNAP 5.9
EMG TA Chronic
neurogenic
Chronic
neurogenic
CMCT TA left/right (N ,16 ms) 21.9/23.4 25.8 25.0/29.7 No MEP
CMCT FDI left/right (N ,8 ms) 8.6/8.9 9.0 9.8/10.6 7.8/7.8
*(1) able to walk unassisted .500 m; (2) able to walk .500 m with walking aid; (3) able to walk ,500 m; (4) not able to walk.
Numbering of individuals corresponds to fig 1.
ASR, Achilles’ tendon reflex; CMAP, compound muscle action potential; CMCT, central motor conduction time; EMG,
electromyography; FDI, first dorsal interosseus muscle; LL, lower limb; MEP, motor evoked potential; MNCV, motor nerve
conduction velocity; N, normal values; PSR, patellar tendon reflex; SNAP, sensory nerve action potential; SNCV, sensory nerve
conduction velocity; TA, tibialis anterior muscle; UL, upper limb.
+, present; –, absent.
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Sistermans (Department of Human Genetics, Radboud University Nijmegen Medical
Centre, The Netherlands) for the SPG4 analysis in the Dutch HSP index cases.
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